

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

IDBS

RRID:SCR_004077

Type: Tool

Proper Citation

IDBS (RRID:SCR_004077)

Resource Information

URL: <http://www.idbs.com/>

Proper Citation: IDBS (RRID:SCR_004077)

Description: Commercial provider of advanced software and solutions that helps R&D teams make discoveries. They provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data. Their technology and domain expertise enables users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Their diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.

Abbreviations: IDBS

Synonyms: ID Business Solutions, ID Business Solutions Ltd., ID Business Solutions Limited

Resource Type: commercial organization

Keywords: pharmaceutical, biotechnology, agricultural science, chemical, energy, engineering, healthcare

Availability: Commercial license

Resource Name: IDBS

Resource ID: SCR_004077

Alternate IDs: nlx_158525

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260905T132514+0000

Ratings and Alerts

No rating or validation information has been found for IDBS.

No alerts have been found for IDBS.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Zhang S, et al. (2025) A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy. *Frontiers in pharmacology*, 16, 1560559.

Falkenstern L, et al. (2024) A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition. *Scientific reports*, 14(1), 1739.

Aguado ME, et al. (2024) Identification and Validation of Compounds Targeting Leishmania major Leucyl-Aminopeptidase M17. *ACS infectious diseases*, 10(6), 2002.

Rasmussen L, et al. (2024) A high-throughput response to the SARS-CoV-2 pandemic. *SLAS discovery : advancing life sciences R & D*, 29(5), 100160.

Whitehead CE, et al. (2024) A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. *Nature cancer*, 5(8), 1250.

Spiliotis K, et al. (2024) Utilising activity patterns of a complex biophysical network model to optimise intra-striatal deep brain stimulation. *Scientific reports*, 14(1), 18919.

Sharma M, et al. (2024) Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. *Molecular cancer therapeutics*, 23(1), 24.

Bianchi M, et al. (2024) The CD33xCD123xCD70 Multispecific CD3-Engaging DARPIn MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. *Cancer immunology research*, 12(7), 921.

Spina JS, et al. (2024) Modulating in vitro lung fibroblast activation via senolysis of senescent human alveolar epithelial cells. *Aging*, 16(13), 10694.

Vinogradova EE, et al. (2023) Synthesis and Evaluation on the Fungicidal Activity of S-Alkyl Substituted Thioglycolurils. *International journal of molecular sciences*, 24(6).

Salimova EV, et al. (2023) 3-Amino-Substituted Analogues of Fusidic Acid as Membrane-Active Antibacterial Compounds. *Membranes*, 13(3).

Chen X, et al. (2023) Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase. *Pharmaceuticals (Basel, Switzerland)*, 16(3).

Savill KMZ, et al. (2022) Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. *Nature communications*, 13(1), 2057.

Wang X, et al. (2022) Schisandrin A from *Schisandra chinensis* Attenuates Ferroptosis and NLRP3 Inflammasome-Mediated Pyroptosis in Diabetic Nephropathy through Mitochondrial Damage by AdipoR1 Ubiquitination. *Oxidative medicine and cellular longevity*, 2022, 5411462.

Milne R, et al. (2022) Toolkit of Approaches To Support Target-Focused Drug Discovery for *Plasmodium falciparum* Lysyl tRNA Synthetase. *ACS infectious diseases*, 8(9), 1962.

Carlson EJ, et al. (2022) Discovery and Characterization of Multiple Classes of Human CatSper Blockers. *ChemMedChem*, 17(15), e202000499.

Yu S, et al. (2022) Genome-wide CRISPR Screening to Identify Drivers of TGF- β -Induced Liver Fibrosis in Human Hepatic Stellate Cells. *ACS chemical biology*, 17(4), 918.

Venzon M, et al. (2022) Microbial byproducts determine reproductive fitness of free-living and parasitic nematodes. *Cell host & microbe*, 30(6), 786.

Xiao H, et al. (2022) Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism. *Acta pharmaceutica Sinica. B*, 12(6), 2887.

van der Weijden F, et al. (2022) The efficacy of a rubber bristles interdental cleaner on parameters of oral soft tissue health-a systematic review. *International journal of dental hygiene*, 20(1), 26.